Becton, Dickinson and Company $BDX Shares Newly Purchased by AIA Group Ltd

Becton, Dickinson and Company logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • AIA Group acquired a new 27,200-share position in Becton, Dickinson and Company during the third quarter, valued at approximately $4.87 million. Institutional investors and hedge funds collectively own 86.97% of the company.
  • BD reported quarterly earnings of $3.23 per share, beating analyst estimates of $3.14, while revenue rose 5.4% year over year to $4.98 billion.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $185.07; company insiders sold 6,907 shares worth about $1.27 million over the past 90 days.
  • Five stocks to consider instead of Becton, Dickinson and Company.

AIA Group Ltd bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 27,200 shares of the medical instruments supplier's stock, valued at approximately $4,869,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Provenance Wealth Advisors LLC raised its stake in shares of Becton, Dickinson and Company by 3,944.4% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 1,456 shares of the medical instruments supplier's stock worth $261,000 after purchasing an additional 1,420 shares during the period. Integrity Alliance LLC. boosted its holdings in shares of Becton, Dickinson and Company by 6.8% in the 3rd quarter. Integrity Alliance LLC. now owns 1,639 shares of the medical instruments supplier's stock worth $293,000 after buying an additional 105 shares during the last quarter. First Nebraska Trust Co bought a new position in Becton, Dickinson and Company during the third quarter valued at about $5,575,000. GRIMES & Co WEALTH MANAGEMENT LLC grew its position in Becton, Dickinson and Company by 352.7% during the third quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 6,632 shares of the medical instruments supplier's stock valued at $1,187,000 after buying an additional 5,167 shares during the period. Finally, Independence Wealth Advisors LLC increased its holdings in Becton, Dickinson and Company by 3.1% during the third quarter. Independence Wealth Advisors LLC now owns 2,033 shares of the medical instruments supplier's stock worth $364,000 after buying an additional 62 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Up 5.3%

BDX opened at $208.57 on Thursday. The stock has a market cap of $57.47 billion, a PE ratio of 15.24, a P/E/G ratio of 13.36 and a beta of 0.22. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $209.84. The business's fifty day simple moving average is $187.23 and its 200 day simple moving average is $170.20.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the business earned $3.68 earnings per share. The business's quarterly revenue was up 5.4% on a year-over-year basis. As a group, research analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Feld sold 165 shares of the firm's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,907 shares of company stock valued at $1,269,128 in the last ninety days. Company insiders own 0.40% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They set an "outperform" rating for the company. Weiss Ratings upgraded shares of Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 28th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Royal Bank Of Canada boosted their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Finally, Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of "Moderate Buy" and an average price target of $185.07.

Get Our Latest Stock Report on Becton, Dickinson and Company

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD's products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.

Recommended Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Becton, Dickinson and Company Right Now?

Before you consider Becton, Dickinson and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.

While Becton, Dickinson and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines